Wednesday, April 22, 2020

Myosana Therapeutics Finds $1M In Funding

Newport Beach-based Myosana Therapeutics, a biotech company which is working on technology for non-viral gene delivery, has raised $1M in its seed funding round, the company said this morning. The funding came from CureDuchenne Ventures. The company said the new funding will go towards development of its non-viral gene therapy, for delivering a treatment for Duchenne muscular dystrophy (DMD). The company said its technology is based on research from the University of Washington School of Medicine, and researchers Nick Whitehead and Stan Froehner. The company explains its technology targetets muscle cells to produce the missing protein caused by a mutation of a gene. Myosana Therapeutics is led by CEO Steve Runnels.